Literature DB >> 786226

Acquired toxoplasmic chorioretinitis.

M Saari, I Vuorre, H Neiminen, S Räisänen.   

Abstract

A patient developed an acquired toxoplasmic chorioretinitis 11 days after exposure to infected animals. As systemic manifestations of the disease, the patient had rhinitis, sore throat, muscular pains, fatigue, cervical lymphadenopathy, and cardiac symptoms, with highly elevated Toxoplasma antibody titers. During treatment with prednisone, the chorioretinal lesion progressed to the macular area, but improvement was seen when pyrimethamine and sulfonamide therapy was started. The importance of this case relates to the unusual occurrence of acquired infection with systemic manifestations in toxoplasmic chorioretinitis and to the possibility of the transmission of toxoplasmosis by trophozoites in excretions.

Entities:  

Mesh:

Year:  1976        PMID: 786226     DOI: 10.1001/archopht.1976.03910040319005

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  5 in total

Review 1.  Toxoplasma gondii and ocular toxoplasmosis: pathogenesis.

Authors:  C E Pavesio; S Lightman
Journal:  Br J Ophthalmol       Date:  1996-12       Impact factor: 4.638

2.  Use of the polymerase chain reaction in the diagnosis of acquired ocular toxoplasmosis in an immunocompetent adult.

Authors:  R M Manners; S O'Connell; E C Guy; D H Joynson; C R Canning; D E Etchells
Journal:  Br J Ophthalmol       Date:  1994-07       Impact factor: 4.638

3.  Retinochoroiditis in acute Epstein-Barr virus infection.

Authors:  S P Kelly; A R Rosenthal; K G Nicholson; C G Woodward
Journal:  Br J Ophthalmol       Date:  1989-12       Impact factor: 4.638

4.  Acute acquired toxoplasmic retinochoroiditis in a patient with anterior uveitis, amplified by immunosuppressive therapy.

Authors:  Andres J Klaeger; Carl P Herbort
Journal:  Int Ophthalmol       Date:  2008-02-23       Impact factor: 2.031

5.  Study of toxoplasmosis and toxocariasis in patients suffering from ophthalmic disorders using serological and molecular methods.

Authors:  Jasem Saki; Elham Eskandari; Mostafa Feghhi
Journal:  Int Ophthalmol       Date:  2020-05-18       Impact factor: 2.031

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.